Medications, Including Injectable Weight-Loss Drugs, Make Up One-Third of VA's Projected 2025 Budget Shortfall
Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as Ozempic and Wegovy, which the Biden administration announced Tuesday should be covered for Medicare patients.
How to preserve muscle mass on weight-loss drugs like Wegovy
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to general weight loss. Is this a real concern, and if so, how can a person maintain their muscle mass on GLP-1 drugs?
Wegovy costs $1,349 in the US vs. $92 in the UK. Why are weight loss drugs so pricey?
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.
Who gets weight loss drugs covered by insurance? In North Carolina, being on Medicaid helps.
North Carolina stopped covering weight loss drugs such as Ozempic for state employees without diabetes. But it extended coverage for Medicaid recipients.
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
Biden's plan to cover anti-obesity drugs could cost $140 billion
President Joe Biden's plan to authorize Medicare and Medicaid cover anti-obesity medications starting in 2026 would $140 billion over the next decade.
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning.
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), challenging a two-decade-old law and facing probable opposition from the incoming Trump administration.
News Medical on MSN3h
Expert explores the expanding applications of GLP1 therapies
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
emjreviews.com8h
Could GLP-1 Drugs Reduce Alcohol Consumption?
A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
The “Holiday Pause” For GLP-1s Is Quickly Approaching — but Is It Safe?
Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...
CMAJ3d
Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...
Medscape2d
Diabetes Drugs Promising for Alcohol Use Disorder
Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...
News Medical on MSN8d
Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption
The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
Popular diabetes and obesity drugs also protect kidneys, study shows
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...